Update on the Covid-19 vaccine

Chronic Obstructive Pulmonary Disease (COPD) refers to several different types of lung disorders, one of which is CO VID-19. This respiratory illness is caused by a virus called SARS-1. People with severe underlying medical conditions such as lung or heart disease or diabetes appear to be at greater risk for contracting COPD 19. Although scientists have yet to identify all the possible triggers of COPD-19, they have identified which group of people are more vulnerable to its effects.

There have been several medical product developers attempting to create a vaccine to combat COPD-19. One of these is Gilead Science with an application called CIVITX. The company hopes that this vaccine will prevent the development of the “silent” but potentially deadly SARS-Covid-2 virus, which causes COPD. Other product developers have created medications to prevent the onset of COPD-related complications in people whose symptoms are caused by smoking or are made from tobacco products. One of these is Generex, which is currently undergoing clinical trials.

In an effort to speed up research and development of the new virus, the US Food and Drug Administration (FDA) issued a draft of a guideline to manufacturers of products containing a known or possible coccinogens. The draft directs manufacturers to provide the FDA with bioprolemics that show how their product is unlikely to cause death or severe health injury to individuals who may be exposed to the product through inhalation, dermal, ingestion or injection. The manufacturers will need to submit final revisions to the guidelines to the FDA by July 14, 2021. The hope is that this update will help speed up the development of the new Covid-19 vaccine.